Lipid Lowering Effect of a Cereal Based Snack Bar With Added Plant Stanol Ester
Effect of a Cereal Based Snack Bar With Added Plant Stanol Ester on Serum Total and Lipoprotein Lipids
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Serum total cholesterol 5.2-8.5 mmol/l
- Serum triglycerides < 3 mmol/l
- Signed written informed consent
Exclusion Criteria:
- Abnormal liver, kidney and thyroid function
- Use of lipid lowering medication
- Consumption of other plant sterol or plant stanol containing food products or supplements, or other foods or supplements for cholesterol lowering 1 month prior to visit 2
- History of unstable coronary artery disease (myocardial infarction, coronary artery bypass graft (CABG), percutaneous transluminal coronary angioplasty (PTCA) within the previous 6 months
- Diagnosed type 1 or type 2 diabetes requiring medical treatment
- History of recent temporal ischemic attack or malignant diseases (< 5 yrs)
- Celiac disease, or allergy or intolerance to the ingredients of the test products
- Medically prescribed diet/medication for slimming or a special diet like very low calorie diet or obesity drug, or vegan and gluten-free diet
- Subjects with alcohol abuse (> 4 portion per day)
- Pregnancy or planned pregnancy or lactating
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Plant stanol ester
Cereal based snack bar with added plant stanol ester (0.8 g plant stanols/bar).
Two bars consumed daily as a snack, between meals, for 4 weeks (1.6 g plant stanols/d).
|
|
|
PLACEBO_COMPARATOR: Placebo
Cereal based snack bar without plant stanol ester.
Two bars consumed daily as a snack, between meals, for 4 weeks (0 g plant stanols/d).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage change in serum LDL cholesterol
Time Frame: 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Absolute change in serum LDL cholesterol (mmol/l)
Time Frame: 4 weeks
|
4 weeks
|
|
Absolute and percentage change in serum total, HDL- and non-HDL cholesterol and serum total triglycerides
Time Frame: 4 weeks
|
4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MFRA004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyslipidemias
-
NCT02262143Completed
-
NCT04643093CompletedPrimary Hypercholesterolemia | Mixed Dyslipidemias
-
NCT07551505Not yet recruiting
-
NCT07543718Recruiting
-
NCT07608705Not yet recruiting
-
NCT07515560Not yet recruiting
-
NCT07515573Not yet recruiting
-
NCT07322016Recruiting
-
NCT07610304Completed
-
NCT07578857Completed
Clinical Trials on Placebo
-
NCT03827590UnknownAcute Bronchitis | Acute Upper Respiratory Tract Infection
-
NCT02177513Completed
-
NCT06767540Not yet recruiting
-
NCT02935712CompletedMale Subjects With Type II Diabetes (T2DM)
-
NCT03198624CompletedPharmacokinetics | Safety Issues
-
NCT02982187CompletedPulmonary Disease, Chronic Obstructive
-
NCT04388215UnknownHypertension | Dyslipidemias
-
NCT04693039Completed
-
NCT01610388Completed